Incidence et prévalence de l, p.27 ,
38 5.1.1 Méthodes de mesure de la densité osseuse, absorptiométrie biphotonique à rayons X (DXA).(9?11), p.40 ,
46 5.2.3.1 Les enzymes reflétant le nombre et l'activité ostéoclastique46 5.2.3.2 Les fragments urinaires de l'ostéocalcine46 5.2.3.3 Les régulateurs de l'activité ostéoclastique (RANk-L et ostéoprotégérine) Les régulateurs de l'activité ostéoblastique.(47), pp.37-4041 ,
72 5.1.1 Inhibiteurs de RANKL(83?85), pp.87-9074 ,
Physiologie humaine. 3ème éd. Pradel, 2001. ,
Principes d'anatomie et de physiologie ,
Le vieillissement osseux : les nouveaux acteurs de communication intercellulaire. Médecine & Longévité, pp.200-204, 2010. ,
DOI : 10.1016/j.mlong.2010.05.001
Les marqueurs biochimiques du remodelage osseux. Gynécologie Obstétrique & Fertilité, pp.1009-1022, 2005. ,
Aromatase et r??gulation du remodelage osseux, Revue du Rhumatisme, vol.73, issue.1, pp.32-40, 2006. ,
DOI : 10.1016/j.rhum.2005.02.010
Nouveaux marqueurs biologiques du remodelage osseux dans l'ostéoporose. Médecine Nucléaire, pp.17-27, 2009. ,
DOI : 10.1016/j.mednuc.2008.09.008
Aromatase Activity and Bone Loss in Men, Journal of Osteoporosis, vol.40, issue.6, p.230671, 2011. ,
DOI : 10.1210/en.2009-0540
Tetracycline-based histological analysis of bone remodeling, Calcified Tissue Research, vol.69, issue.1, pp.211-248, 1969. ,
DOI : 10.1007/BF02058664
Osteoporose : prevention, diagnostic, traitement. Paris: Maloine, 2003. ,
Prevalence and features of osteoporosis in the French general population: The Instant study, Joint Bone Spine, vol.76, issue.4, pp.394-400, 2009. ,
DOI : 10.1016/j.jbspin.2008.10.008
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006. ,
DOI : 10.1016/j.urology.2005.07.017
Mortality and morbidity after hip fractures, BMJ, vol.308, issue.6924, p.343, 1994. ,
DOI : 10.1136/bmj.308.6924.343b
Epidemiology of osteoporosis-related fractures in France: A literature review, Joint Bone Spine, vol.77, issue.6, pp.546-51, 2010. ,
DOI : 10.1016/j.jbspin.2010.02.006
Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database, Osteoporosis International, vol.13, issue.12, pp.1475-80, 2005. ,
DOI : 10.1007/s00198-005-2031-0
Costs and quality of life associated with osteoporosis-related fractures in Sweden, Osteoporosis International, vol.7, issue.Suppl 2, pp.637-50, 2006. ,
DOI : 10.1007/s00198-005-0015-8
Report on Osteoporosis in the European Community: Current Status and Recommendations for the Future, Osteoporosis International, vol.8, issue.6, pp.531-535, 1998. ,
DOI : 10.1007/s001980050094
Age-Related Femoral Bone Loss in Men: Evidence for Hyperparathyroidism and Insulin-Like Growth Factor-1 Deficiency, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol.59, issue.12, pp.1285-1294, 2004. ,
DOI : 10.1093/gerona/59.12.1285
A prospective study on socioeconomic aspects of fracture of the proximal femur, Journal of Bone and Mineral Research, vol.307, issue.12, pp.1935-1977, 1996. ,
DOI : 10.1002/jbmr.5650111215
Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporosis International, vol.89, issue.10, pp.1319-1347, 2007. ,
DOI : 10.1007/s00198-007-0394-0
Ost??oporose et h??parine, Revue du Rhumatisme, vol.68, issue.8, pp.727-735, 2001. ,
DOI : 10.1016/S1169-8330(01)00172-7
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer, Urology, vol.57, issue.1, pp.127-159, 2001. ,
DOI : 10.1016/S0090-4295(00)00895-5
Increased fracture rate in women with breast cancer: a review of the hidden risk, BMC Cancer, vol.122, issue.Suppl 1, p.384, 2011. ,
DOI : 10.1007/s10549-010-0935-7
Contr??le central de la masse osseuse??: implications th??rapeutiques potentielles, Revue du Rhumatisme, vol.72, issue.10-11, pp.887-896, 2005. ,
DOI : 10.1016/j.rhum.2005.09.004
inhibiteurs sélectifs de la recapture de la sérotonine et ostéoporose ,
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture, JAMA, vol.296, issue.24, pp.2947-53, 2006. ,
DOI : 10.1001/jama.296.24.2947
Use of proton pump inhibitors and risk of osteoporosis-related fractures, CMAJ août, vol.12179, issue.4, pp.319-345, 2008. ,
Association Between Alcohol Consumption and Both Osteoporotic Fracture and Bone Density, The American Journal of Medicine, vol.121, issue.5, pp.406-424, 2008. ,
DOI : 10.1016/j.amjmed.2007.12.012
Les marqueurs biochimiques du remodelage osseux. Gynécologie Obstétrique & Fertilité, pp.1009-1022, 2005. ,
Nouveaux marqueurs biologiques du remodelage osseux dans l'ostéoporose. Médecine Nucléaire, pp.17-27, 2009. ,
DOI : 10.1016/j.mednuc.2008.09.008
Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs, Osteoporosis International, vol.11, issue.0, pp.66-76, 2000. ,
DOI : 10.1007/s001980070007
Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover, Journal of Bone and Mineral Research, vol.133, issue.1, pp.1804-1816, 2005. ,
DOI : 10.1359/JBMR.050403
Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption, Journal of Bone and Mineral Research, vol.14, issue.7, pp.1337-1382, 2000. ,
DOI : 10.1359/jbmr.2000.15.7.1337
Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies, Journal of Bone and Mineral Research, vol.11, issue.Suppl 1, pp.464-473, 1999. ,
DOI : 10.1359/jbmr.1999.14.3.464
Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women, Journal of Bone and Mineral Research, vol.3, issue.Suppl 6, pp.386-93, 2004. ,
DOI : 10.1359/JBMR.0301244
Biochemical Markers of Bone Metabolism: An Overview, Clinical Biochemistry, vol.30, issue.8, pp.573-93, 1997. ,
DOI : 10.1016/S0009-9120(97)00113-6
A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients, Bone, vol.31, issue.1, pp.62-71, 2002. ,
DOI : 10.1016/S8756-3282(02)00793-7
Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b, Clinica Chimica Acta, vol.376, issue.1-2, pp.205-217, 2007. ,
DOI : 10.1016/j.cca.2006.08.021
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies, Osteoporosis International, vol.15, issue.Suppl 1, pp.339-387, 2008. ,
DOI : 10.1007/s00198-007-0462-5
Age-related changes in the collagen network and toughness of bone, Bone, vol.31, issue.1, pp.1-7, 2002. ,
DOI : 10.1016/S8756-3282(01)00697-4
Nouvelles cibles thérapeutiques dans l'ostéoporose . Revue du Rhumatisme. 2010 ? mai, pp.257-63 ,
DOI : 10.1016/j.rhum.2009.10.032
Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study, Journal of Bone and Mineral Research, vol.18, issue.Suppl 6, pp.1813-1822, 2005. ,
DOI : 10.1359/JBMR.050609
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis, BMJ, vol.342, issue.apr19 1, pp.2040-2040 ,
DOI : 10.1136/bmj.d2040
Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older, New England Journal of Medicine, vol.337, issue.10, pp.670-676, 1997. ,
DOI : 10.1056/NEJM199709043371003
Estimation du statut en vitamines et minéraux de la population française d'après des enquêtes récentes, pp.77-87, 1999. ,
Nutrition et vieillissement osseuxL'ostéoporose. Nutrition Clinique et Métabolisme, pp.212-220, 2004. ,
DOI : 10.1016/j.nupar.2004.10.005
Ost??oporose et pr??vention nutritionnelle, EMC - Endocrinologie - Nutrition, vol.7, issue.3, 2010. ,
DOI : 10.1016/S1155-1941(10)51201-0
Bisphosphonate treatment of bone disease Archives of Disease in Childhood, pp.494-503, 2005. ,
Bisphosphonates: Mode of Action and Pharmacology, PEDIATRICS, vol.119, issue.Supplement, pp.150-162, 2007. ,
DOI : 10.1542/peds.2006-2023H
Effets des??traitements de??l'ost??oporose sur??la??qualit?? osseuse, Revue du Rhumatisme, vol.74, issue.1, pp.43-51, 2007. ,
DOI : 10.1016/j.rhum.2006.06.008
Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort, Journal of Bone and Mineral Research, vol.280, issue.(Suppl 3), pp.993-1001, 2011. ,
DOI : 10.1002/jbmr.288
Studies Probe Possible Link Between Bisphosphonates and Femoral Fractures, JAMA, vol.303, issue.18 ,
DOI : 10.1001/jama.2010.576
Available de, Internet]. [cité 2012 févr 2]Press_release, 2011. ,
Les SERMs dans le traitement de l'ostéoporose : état des lieux et perspectives. Gynécologie Obstétrique & Fertilité, pp.423-431, 2006. ,
DOI : 10.1016/j.gyobfe.2006.03.004
Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.9, pp.4206-4219, 2003. ,
DOI : 10.1210/jc.2002-021877
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, pp.637-682, 1999. ,
DOI : 10.1001/jama.282.7.637
Sodium nitroprussideinduced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene, Biochem. Pharmacol. mars, vol.1569, issue.6, pp.891-901, 2005. ,
Le guide pharmaco clinique. Rueil-Malmaison: le Moniteur des pharmacies, 2009. ,
Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation, Endocrinology, vol.142, issue.9, pp.4047-54, 2001. ,
DOI : 10.1210/en.142.9.4047
Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of Its Resorptive Action: Differential Effects of Intermittent and Continuous Administration*, Endocrinology, vol.110, issue.2, pp.506-518, 1982. ,
DOI : 10.1210/endo-110-2-506
The Anabolic Effects of Parathyroid Hormone, Osteoporosis International, vol.13, issue.4, pp.267-77, 2002. ,
DOI : 10.1007/s001980200026
Rôle de la parathormone dans l'ostéoporose. La Presse Médicale, pp.495-501, 2006. ,
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.344, issue.19, pp.1434-1475, 2001. ,
DOI : 10.1056/NEJM200105103441904
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis, Annals of Internal Medicine, vol.146, issue.5, pp.326-365, 2007. ,
DOI : 10.7326/0003-4819-146-5-200703060-00005
Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women, Journal of Bone and Mineral Research, vol.132, issue.Suppl 1, pp.1051-1056, 1998. ,
DOI : 10.1359/jbmr.1998.13.6.1051
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis, Osteoporosis International, vol.17, issue.12, pp.1663-73, 2009. ,
DOI : 10.1007/s00198-008-0825-6
Ran??late de strontium : une nouvelle approche de l'ost??oporose post-m??nopausique, Revue du Rhumatisme, vol.72, issue.S1, pp.16-22, 2005. ,
DOI : 10.1016/S1169-8330(05)80004-3
Ran??late de strontium (Protelos??)??: effets ind??sirables rapport??s en France, La Presse M??dicale, vol.40, issue.10, pp.453-462, 2011. ,
DOI : 10.1016/j.lpm.2011.07.010
Nouvelles cibles thérapeutiques dans l'ostéoporose . Revue du Rhumatisme. 2010 ? mai, pp.257-63 ,
DOI : 10.1016/j.rhum.2009.10.032
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, New England Journal of Medicine, vol.361, issue.8, pp.756-65, 2009. ,
DOI : 10.1056/NEJMoa0809493
Innovations thérapeutiques dans l'ostéoporose (anticorps antisclérostine et denosumab) Annales d'Endocrinologie, pp.15-22, 2011. ,
DOI : 10.1016/s0003-4266(11)70005-1
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density, Journal of Bone and Mineral Research, pp.091029141139034-41, 2009. ,
DOI : 10.1359/jbmr.091035
Anoikis mechanisms, Current Opinion in Cell Biology, vol.13, issue.5, pp.555-62, 2001. ,
DOI : 10.1016/S0955-0674(00)00251-9
Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.4, pp.2022-2030, 2005. ,
DOI : 10.1210/jc.2004-2126
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J. Pharmacol. Exp. Ther, vol.291, issue.2, pp.612-619, 1999. ,
Integrin Regulates Osteoclast Apoptosis by Transmitting a Positive Death Signal, Molecular Endocrinology, vol.19, issue.3, pp.771-80, 2005. ,
DOI : 10.1210/me.2004-0161
Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use, Endocrine Reviews, vol.26, issue.5, pp.688-703, 2005. ,
DOI : 10.1210/er.2004-0006
The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.8, pp.2441-2450, 2011. ,
DOI : 10.1210/jc.2010-2855
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist, The EMBO Journal, vol.262, issue.23, pp.6267-76, 2003. ,
DOI : 10.1093/emboj/cdg599
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*, Journal of Bone and Mineral Research, vol.24, issue.4, pp.578-88, 2009. ,
DOI : 10.1359/jbmr.081206
Bone mass is inversely proportional to Dkk1 levels in mice, Bone, vol.41, issue.3, pp.331-340, 2007. ,
DOI : 10.1016/j.bone.2007.05.009
Generation and Selection of Novel Fully Human Monoclonal Antibodies That Neutralize Dickkopf-1 (DKK1) Inhibitory Function in Vitro and Increase Bone Mass in Vivo, Journal of Biological Chemistry, vol.285, issue.51, pp.40135-40182, 2010. ,
DOI : 10.1074/jbc.M110.166892
Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine, pp.1-7, 2006. ,
The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France, Clinical Therapeutics, vol.28, issue.10, pp.1686-94, 2006. ,
DOI : 10.1016/j.clinthera.2006.10.013